Basic Stats
| LEI | 529900DG3YQA5XIHV057 |
| CIK | 1411906 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ampio Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| January 29, 2025 |
Denver City & District Building 1437 Bannock Street, Room 256 Denver, CO 80202 Exhibit 99.2 DISTRICT COURT, CITY & COUNTY OF DENVER, STATE OF COLORADO 1437 Bannock Street Denver, Colorado 80202 COURT USE ONLY Plaintiff: JORDAN LEAJAMES (MCCANN), Derivatively on Behalf of AMPIO Case Number: 2023CV30287 PHARMACEUTICALS, INC., Division: 280 v. Defendants: MICHAEL A. MARTINO, J. KEVIN BUCHI, DAVID STEVENS, ELIZABETH JOBES, HOLLI CHEREVKA, DAVID BAR-OR, PHILIP H. COELHO, and RICH |
|
| January 29, 2025 |
Denver City & District Building 1437 Bannock Street, Room 256 Denver, CO 80202 Exhibit 99.1 DISTRICT COURT, CITY & COUNTY OF DENVER, STATE OF COLORADO 1437 Bannock Street Denver, Colorado 80202 COURT USE ONLY Plaintiff: JORDAN LEAJAMES (MCCANN), Derivatively on Behalf of AMPIO PHARMACEUTICALS, INC., Case Number: 2023CV30287 Division: 280 v. Defendants: MICHAEL A. MARTINO, J. KEVIN BUCHI, DAVID STEVENS, ELIZABETH JOBES, HOLLI CHEREVKA, DAVID BAR-OR, PHILIP H.COELHO, and RICHA |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35182 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-35182 AMPIO PHARMACEUTICALS, INC. NYSE American (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed or registered) 9800 Mount Pyramid |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35182 AMPIO PHARMACEUTICALS, INC. (Exact |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2024 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commiss |
|
| March 25, 2024 |
Ampio Announces Voluntary Delisting and SEC Deregistration Exhibit 99.1 Ampio Announces Voluntary Delisting and SEC Deregistration ENGLEWOOD, Colo., March 25, 2024 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”) today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under |
|
| February 28, 2024 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2024 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Comm |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
AMPIO PHARMACEUTICALS, INC. 9800 Mount Pyramid Court, Suite 400 Englewood, Colorado 80112 AMPIO PHARMACEUTICALS, INC. 9800 Mount Pyramid Court, Suite 400 Englewood, Colorado 80112 February 28, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Ampio Pharmaceuticals, Inc. - Request to Withdraw Registration Statement on Form S-1 (File No. 333-276198) Ladies and Gentlemen: Pursuant to Rule 477 under the Securiti |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 15, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2024 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Comm |
|
| February 15, 2024 |
Ampio Provides Update on Results from Pre-IND Enabling Studies Exhibit 99.1 Ampio Provides Update on Results from Pre-IND Enabling Studies ENGLEWOOD, Colo., February 14, 2024 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed non |
|
| January 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2024 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| January 25, 2024 |
AMPIO PHARMACEUTICALS, INC. Common Stock Table of Contents PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To Prospectus dated September 27, 2023) Registration Number 333-274558 AMPIO PHARMACEUTICALS, INC. |
|
| January 24, 2024 |
AMPIO PHARMACEUTICALS, INC. Common Stock Table of Contents PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To Prospectus dated September 18, 2023) Registration Number 333-274558 AMPIO PHARMACEUTICALS, INC. |
|
| January 11, 2024 |
Ampio Provides Litigation Update Reports Settlement in Principle of Certain Pending Legal Actions Exhibit 99.1 Ampio Provides Litigation Update Reports Settlement in Principle of Certain Pending Legal Actions ENGLEWOOD, Colo., January 11, 2024 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has re |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2024 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| December 21, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) AMPIO PHARMACEUTICALS, INC. |
|
| December 21, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on December 21, 2023 Registration No. |
|
| December 7, 2023 |
AMPE / Ampio Pharmaceuticals Inc / Terker Bruce E - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Ampio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 03209T109 (CUSIP Number) November 30, 2023** (Date of Event Which Requires Filing of This Statement) Check the appropriate box t |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-351 |
|
| November 2, 2023 |
Exhibit 99.1 Ampio Pharmaceuticals 1 Emerging Growth Conference November 02, 2023 iStock Caution Regarding Forward-Looking Statements • This presentation may contain forward-looking statements. All statements other than statements of historical facts contained in this letter, including statements regarding our anticipated future clinical developments, future financial position, and plans and objec |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| October 27, 2023 |
Ampio Pharmaceuticals, Inc. Compensation Recoupment Policy Adopted October 24, 2023. Exhibit 10.1 Ampio Pharmaceuticals, Inc. Compensation Recoupment Policy I.Introduction The Board of Directors (the “Board”) of Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incen |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commis |
|
| October 6, 2023 |
Exhibit 99.1 Transcript of Interview with Michael A. Martino, CEO of Ampio Pharmaceuticals, Inc. October 5, 2023 Emerging Growth Conference 1. Ana Berry of Emerging Growth Conference: Welcome back everyone. Next we have Ampio Pharmaceuticals, Inc., which trades on the Nasdaq1 [sic] under the symbol AMPE. It’s a development stage biopharmaceutical company focused on the discovery and development of |
|
| October 4, 2023 |
Exhibit 10.1 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 to Employment Agreement (this “Amendment”) is made and entered into as of October 1, 2023 (the “Effective Date”) by and among Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Michael A. Martino (the “Employee”). RECITALS WHEREAS, the Company and the Employee have entered into that certain Employment Ag |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commis |
|
| September 26, 2023 |
Ampio Pharmaceuticals, Inc. 9800 Mount Pyramid Court, Suite 400 Englewood, Colorado 80112 September 26, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re:Ampio Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-274558 Ladies and Gentlemen: In accordance with Rule 461 under the Securiti |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 18, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Com |
|
| September 18, 2023 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT September 18, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Ampio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, w |
|
| September 18, 2023 |
As filed with the Securities and Exchange Commission on September 18, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 18, 2023 Registration No. |
|
| September 18, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Ampio Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registrati |
|
| August 31, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF AMPIO PHARMACEUTICALS, INC. Ampio Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, does hereby certify as follows: 1.The name of the corporation is Ampio Pharmaceuticals, Inc. (the “Corporation”). 2.The Board of Directors of the Corporation duly adopted a resolution in ac |
|
| August 31, 2023 |
Ampio Pharmaceuticals Announces Reverse Stock Split Exhibit 99.1 Ampio Pharmaceuticals Announces Reverse Stock Split ENGLEWOOD, Colo., August 31, 2023 /PRNewswire/ – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 4:01pm ET on September 11, 2023. The Company’s common |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commis |
|
| August 15, 2023 |
As filed with the Securities and Exchange Commission on August 15, 2023 As filed with the Securities and Exchange Commission on August 15, 2023 Registration No. |
|
| August 15, 2023 |
EXHIBIT 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ampio Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee E |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35182 AM |
|
| August 1, 2023 |
Ampio Pharmaceuticals, Inc. 2023 Stock and Incentive Plan Exhibit 10.1 AMPIO PHARMACEUTICALS, INC.- 2023 STOCK AND INCENTIVE PLAN SECTION 1.GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Ampio Pharmaceuticals, Inc. (the “Company”) 2023 Stock and Incentive Plan (the “Plan”). The purpose of the Plan is to enable the Company and its Subsidiaries to attract and retain officers, employees, Non-Employee Directors and other key persons (in |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commissi |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commissio |
|
| June 14, 2023 |
Proposal No. 4 – Approval of the 2023 Stock and Incentive Plan Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| June 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| May 26, 2023 |
Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock Exhibit 99.1 Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock ENGLEWOOD, Colo., May 26, 2023 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstandin |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commissio |
|
| May 26, 2023 |
Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF AMPIO PHARMACEUTICALS, INC. Effective May 24, 2023, Article III, Section 8 of the bylaws of Ampio Pharmaceuticals, Inc. was amended to read in its entirety as follows: Section 8. Quorum. At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of Incorporation, or by these Bylaws, the presence, in |
|
| May 26, 2023 |
Exhibit 3.2 AMPIO PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF SERIES D PREFERRED STOCK PURSUANT TO SECTION 151 OF THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Boar |
|
| May 8, 2023 |
Exhibit 10.1 SUBLEASE AGREEMENT This Sublease Agreement (“Sublease”) is made and entered into this 16th day of February, 2023 (the “Effective Date”), by and between, Ampio Pharmaceuticals, Inc., a Delaware Corporation (“Sublandlord”), and Utility Global, Inc., a Delaware corporation (“Subtenant”). WHEREAS, Sublandlord entered into that certain Lease Agreement by and between NCWP – Inverness Busine |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35182 A |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35182 AMPIO PHARMACE |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commiss |
|
| April 18, 2023 |
Ampio Pharmaceuticals Issues Letter to Stockholders Exhibit 99.1 Ampio Pharmaceuticals Issues Letter to Stockholders ENGLEWOOD, Colo., Apr. 18, 2023 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino. Dear Ampio Stockholders: On March 27, 2023, we filed our 2022 Annual Report on Form 10-K. In this letter we w |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35182 AMPIO PHARMACEUTICALS, INC. (Exact |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commiss |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 1, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commissi |
|
| February 2, 2023 |
AMPE / Ampio Pharmaceuticals Inc / Terker Bruce E - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Ampio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 03209T109 (CUSIP Number) December 31, 2022** (Date of Event Which Requires Filing of This Statement) Check the appropriate box t |
|
| January 17, 2023 |
Ampio Pharmaceuticals Issues Letter to Stockholders Exhibit 99.1 Ampio Pharmaceuticals Issues Letter to Stockholders ENGLEWOOD, Colo., Jan. 17, 2023 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino. Dear Fellow Ampio Stockholders: 2022 was a challenging year for our company. We continue to receive update re |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 17, 2023 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| December 27, 2022 |
Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards Exhibit 99.1 Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards ENGLEWOOD, Colo., Dec. 27, 2022 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today announced that it has received notification from The NYSE American LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing standards. S |
|
| December 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 27, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporat |
|
| November 18, 2022 |
Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension Exhibit 99.1 Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension ENGLEWOOD, Colo., Nov. 17, 2022 – Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE) (the “Company”) received notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspe |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 17, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Comm |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 9, 2022 |
Exhibit 99.1 Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split The Reverse Stock Split Will Take Effect November 9, 2022 at 4:01 p.m. ET ENGLEWOOD, Colo., November 8, 2022 — Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), announced today that effective November 9, 2022 at 4:01 p.m. Eastern Time, the Company will amend its certificate of incorporation to implement a fif |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF AMPIO PHARMACEUTICALS, INC. Ampio Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, does hereby certify as follows: 1.The name of the corporation is Ampio Pharmaceuticals, Inc. (the “Corporation”). 2.The Board of Directors of the Corporation duly adopted a resolution in ac |
|
| October 14, 2022 |
Exhibit 99.1 Ampio Pharmaceuticals Issues Letter to Stockholders Proposal to Authorize Reverse Stock Split has Been Approved ENGLEWOOD, Colo., October 14, 2022 ? Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi, and Chief Executive Officer, Mike Martino. ? Dear Fellow Ampio Stockholder, ? On behalf of the |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 13, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| October 4, 2022 |
Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings Exhibit 99.1 Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings ENGLEWOOD, Colo., October 4, 2022 ? Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the ?Company?) received written notification from NYSE American LLC (?NYSE American? or the ?Exchange?) stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company?s common st |
|
| October 4, 2022 |
DEFA14A 1 tmb-20221004xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| October 4, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporatio |
|
| October 4, 2022 |
DEFA14A 1 tmb-20221004xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| September 12, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definiti |
|
| September 1, 2022 |
Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT ? This Amendment No. 1 to Employment Agreement (this ?Amendment?) is made and entered into as of August 30, 2022 by and among Ampio Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and Michael A. Martino (the ?Employee?). ? RECITALS ? WHEREAS, the Company and the Employee have entered into that certain Employment Agreement dated Nov |
|
| September 1, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporatio |
|
| August 29, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definiti |
|
| August 12, 2022 |
Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporatio |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 4, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| August 3, 2022 |
Exhibit 99.1 Ampio Pharmaceuticals’ Chairman of the Board Kevin Buchi and CEO Mike Martino Issues Letter to Stockholders ENGLEWOOD, Colo., August 3, 2022 — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino. Dear Fellow Stockholders, On behalf of the Board and management tea |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commiss |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? D |
|
| July 5, 2022 |
? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| June 24, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) |
|
| June 13, 2022 |
PRE 14A 1 ampe-20220810xpre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| June 2, 2022 |
Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) |
|
| June 2, 2022 |
Ampio Pharmaceuticals’ CEO Mike Martino Issues Letter to Stockholders Exhibit 99.1 ? Ampio Pharmaceuticals? CEO Mike Martino Issues Letter to Stockholders ? ENGLEWOOD, Colo., June 2, 2022 ? Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter |
|
| June 1, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) |
|
| May 16, 2022 |
Ampio Independent Committee to Conduct Investigation Exhibit 99.1 Ampio Independent Committee to Conduct Investigation ? Englewood, CO ? May 16, 2022 ? Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (?Ampio? or the ?Company?) today announced that an independent special committee of the Ampio Board of Directors (the ?Committee?), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relate |
|
| May 16, 2022 |
Research Services Agreement between the Registrant and Trauma Research LLC, dated February 4, 2022.* Exhibit 10.1 ? RESEARCH SERVICES AGREEMENT This Research Services Agreement ("Agreement") is made on February 4, 2022 ("Effective Date"), and entered into by and between Ampio Pharmaceuticals, Inc., a Delaware corporation, having its address at 373 Inverness Parkway, Suite 200 Englewood, Colorado 80112 ("Company") and Trauma Research LLC, a Colorado limited liability company, having its address at |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) |
|
| May 16, 2022 |
Personal Services Agreement between the Registrant and Dr. Bar-Or, dated February 4, 2022.* Exhibit 10.2 ? PERSONAL SERVICES AGREEMENT ? This Personal Services Agreement ("Agreement") is made on February 4, 2022 ("Effective Date") and entered into by and between Ampio Pharmaceuticals, Inc., a Delaware corporation, having its address at 373 Inverness Parkway, Suite 200 Englewood, Colorado 80112 ("Company") and Dr. David Bar-Or, an individual residing at 900 East Oxford Lane, Englewood CO |
|
| May 16, 2022 |
Press Release of Ampio Pharmaceuticals, Inc. Issued May 16, 2022.* Exhibit 99.1 Ampio Independent Committee to Conduct Investigation ? Englewood, CO ? May 16, 2022 ? Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (?Ampio? or the ?Company?) today announced that an independent special committee of the Ampio Board of Directors (the ?Committee?), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relate |
|
| May 16, 2022 |
Ampio Pharmaceuticals Reports First-Quarter Financial Results Exhibit 99.2 ? Ampio Pharmaceuticals Reports First-Quarter Financial Results ? ENGLEWOOD, Colo., May 16, 2022 /PRNewswire/ ? Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial result |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 2, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2022 |
AMPE / Ampio Pharmaceuticals Inc / Terker Bruce E - SC 13G/A Passive Investment SC 13G/A 1 d355719dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Ampio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 03209T109 (CUSIP Number) April 27, 2022** (Date of Event Which Requires Filing of This Statement) |
|
| April 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation |
|
| April 28, 2022 |
ENGLEWOOD, Colo., April 28, 2022 -- Exhibit 99.1 ? ? ENGLEWOOD, Colo., April 28, 2022 - Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) Conference Call Script ? Dan Stokely ? Thank you, Operator. This is Dan Stokely, CFO. Welcome to Ampio Pharmaceuticals, Inc.?s April 28th conference call to provide a further update with respect to the Food and Drug Administration?s response to our AP-013 study. Our Chief Executive Officer ? Mike |
|
| April 21, 2022 |
Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 21, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation |
|
| April 21, 2022 |
AMPIO PROVIDES REGULATORY UPDATE Exhibit 99.1 ? ? AMPIO PROVIDES REGULATORY UPDATE ? ? ? ENGLEWOOD, Colo., April 20, 2022 - Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today announced the receipt of written responses from the United |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation |
|
| March 29, 2022 |
Exhibit 10.7 ? EXECUTION COPY ? EMPLOYMENT AGREEMENT ? This Employment Agreement (the "Agreement") is effective as of October 11, 2021 (the ?Effective Date?), between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Holli Cherevka, (?Employee"). RECITALS WHEREAS, the Compan |
|
| March 29, 2022 |
Exhibit 99.1 Ampio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational Highlights ? Cash and Cash Equivalents of $34 Million Expected to Fund Current Operations into 2H 2023 ? Company to host Conference Call Tuesday, March 29, 2022, at 4:30pm EDT ? ENGLEWOOD, CO, March 29, 2022 ? Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company |
|
| March 29, 2022 |
Exhibit 10.5 ? EXECUTION COPY ? EMPLOYMENT AGREEMENT ? This Employment Agreement (the "Agreement") is effective as of October 11, 2021 (the ?Effective Date?), between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA (hereinafter referred to as the "Company"), and Michael Macaluso (?Employee"). RECITALS WHEREAS, the Compa |
|
| March 29, 2022 |
Exhibit 10.8 ? EXECUTION COPY ? EMPLOYMENT AGREEMENT ? This Employment Agreement (the "Agreement") is effective as of October 11, 2021 (the ?Effective Date?), between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA (hereinafter referred to as the "Company"), and Daniel Stokely (?Employee"). RECITALS WHEREAS, the Company |
|
| March 29, 2022 |
Exhibit 10.4 AMPIO PHARMACEUTICALS, INC. 2019 STOCK AND INCENTIVE PLAN ???????????????? NOTICE OF GRANT OF RESTRICTED STOCK ???????????????? Ampio Pharmaceuticals, Inc. (?Company?), pursuant to the Ampio Pharmaceuticals, Inc. 2019 Stock and Incentive Plan (?Plan?), hereby grants you the opportunity under the Plan to receive Restricted Stock as of the ?Grant Date? set forth below. ? Participant Nam |
|
| March 29, 2022 |
Specimen Common Stock Certificate of the Registrant. Exhibit 4.1 ? ? ? INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AUTHORIZED: 300,000,000 COMMON SHARES, $0.0001 PAR VALUE PER SHARE SEE REVERSE FOR CERTAIN DEFINITIONS This Certifies That is the owner of Fully Paid and Non-Assessable Common Stock, $0.0001 Par Value of AMPIO PHARMACEUTICALS, INC. transferable on the books of this Corporation in person or by attorney upon surrender of this Cer |
|
| March 29, 2022 |
? Exhibit 10.11 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of , 2021 between Ampio Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequate |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commissi |
|
| March 2, 2022 |
Clinical Detail March 2022 Exhibit 99.2 Study AP-013 pivotal trial in OAK Study AP-013 is designed to confirm efficacy observed in first pivotal study AP-003-A to support an Ampion BLA Study AP-013 designed to evaluate independent endpoints in pain and function, which means the study had more patients than required to power pain alone FDA advised a trial with a sole endpoint in pain, with trends i |
|
| March 2, 2022 |
Exhibit 99.1 Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion? Targeting Severe Osteoarthritis of the Knee (OAK) Complete analysis of AP-013 data show Ampion reduced pain with statistical significance The U.S. Food and Drug Administration has Confirmed Ampio?s Type C Meeting Request Company to host a webinar to present data analysis, Wednesday, March 2, 2022, at 4:30p |
|
| February 10, 2022 |
Ampio Expands Board of Directors with Addition of Elizabeth Varki Jobes Exhibit 99.1 ? ? Ampio Expands Board of Directors with Addition of Elizabeth Varki Jobes ? ENGLEWOOD, Colo., Feb. 10, 2022 - Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointment of Elizabeth Varki Jobes, Esq. to the Company?s Board of Directors. The ap |
|
| February 10, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 4, 2022 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporati |
|
| December 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporat |
|
| December 16, 2021 |
Ampio Pharmaceuticals’ CEO Mike Martino Issues Letter to Stockholders Exhibit 99.1 ? ? Ampio Pharmaceuticals? CEO Mike Martino Issues Letter to Stockholders ENGLEWOOD, Colo., Dec. 16, 2021 - Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino. Dear Fello |
|
| December 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporat |
|
| December 15, 2021 |
EX-4.1 2 ampe-20211213xex4d1.htm EX-4.1 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT AMPIO PHARMACEUTICALS, INC. Warrant Shares: [] Initial Exercise Date: December , 2021 Issue Date: December , 2021 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condi |
|
| December 15, 2021 |
EX-10.2 5 ampe-20211213xex10d2.htm EX-10.2 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 13, 2021 and is between Ampio Pharmaceuticals, Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and ass |
|
| December 15, 2021 |
EX-10.1 4 ampe-20211213xex10d1.htm EX-10.1 Exhibit 10.1 December 13, 2021 Ampio Pharmaceuticals, Inc. 373 Inverness Parkway, Suite 200 Englewood, Colorado 80112 Attn: Michael Martino, Chief Executive Officer To Whom It May Concern: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Ampio Pharmaceuticals, Inc., a Delaware corp |
|
| December 15, 2021 |
AMPIO PHARMACEUTICALS ANNOUNCES PRICING OF $22.5 MILLION REGISTERED DIRECT OFFERING Exhibit 99.1 AMPIO PHARMACEUTICALS ANNOUNCES PRICING OF $22.5 MILLION REGISTERED DIRECT OFFERING ENGLEWOOD, Colo., Dec. 13, 2021 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it has entered into definitive agreements with institutional investors fo |
|
| December 14, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237723 PROSPECTUS SUPPLEMENT (To Prospectus dated May 6, 2020) 25,000,000 Shares of Common Stock and Warrants to Purchase up to 15,000,000 Shares of Common Stock Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals, Inc. (the ?Company,? ?we,? ?our,? or ?us?) is offering to investors 25,000,000 shares (the ?Shares?) of our common |
|
| November 29, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporat |
|
| November 29, 2021 |
EX-10.1 2 ampe-20211122xex10d1.htm EX-10.1 Exhibit 10.1 EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is effective as of November 22, 2021 (the “Effective Date”), between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA (hereinafter referred to as the "Company"), and Michael Martino (“Em |
|
| November 29, 2021 |
Exhibit 99.1 ? ? ? Board Member Michael Martino to Become Interim Chairman and CEO of Ampio Pharmaceuticals, Mike Macaluso to Take Medical Leave ? ENGLEWOOD, CO, November 22, 2021 ? Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced that Mike Macaluso is taking a on |
|
| November 10, 2021 |
EX-99.1 2 ampe-20211110xex99d1.htm EX-99.1 Exhibit 99.1 Ampio Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides Business Update Further details to be discussed on this afternoon’s conference call ENGLEWOOD, CO, November 10, 2021 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies f |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporat |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 15, 2021 |
Ampio Pharmaceuticals Strengthens Management Team and Board of Directors EX-99.1 2 ampe-20211011xex99d1.htm EX-99.1 Exhibit 99.1 Ampio Pharmaceuticals Strengthens Management Team and Board of Directors ● Holli Cherevka promoted to President and Chief Operating Officer ● Howard Levy joins as Chief Medical Officer ● J. Kevin Buchi and Michael A. Martino join Board of Directors ● Mike Macaluso, CEO of Ampio, realigns his responsibilities with the Ampio executive team and |
|
| October 15, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 11, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporati |
|
| September 15, 2021 |
Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of EX-99.1 2 ampe-20210915xex99d1.htm EX-99.1 Exhibit 99.1 Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK) ● Ampion™ demonstrated statistically significant reduction in pain and improvement in function at 12 weeks in severe OAK patients ● Results reflect strong safety profile with no treatm |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Com |
|
| August 18, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commis |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation |
|
| August 4, 2021 |
? ? Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update ? Further details to be discussed on this afternoon?s conference call ? ? ENGLEWOOD, CO, August 4, 2021 ? Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? D |
|
| June 30, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definiti |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) ( |
|
| May 5, 2021 |
EX-99.1 2 ampe-20210505xex99d1.htm EX-99.1 Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Progress achieved across therapeutic platform, including in the AP-013 Phase III trial of Ampion™ in Osteoarthritis of the Knee (OAK) Initiated two Phase II trials utilizing Ampion in COVID-19; in an inhaled form for lung inflammation and intravenously; c |
|
| May 5, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 3, 2021 |
Ampio Pharmaceuticals, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update FDA recommends we conduct a randomized, double-blinded, placebo-controlled Phase II for Intravenous (IV) and Inhaled Ampion to allow consideration of EUA treatment of COVID-19 patients ENGLEWOOD, CO, March 3, 2021 – Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused |
|
| March 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 3, 2021 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) |
|
| March 3, 2021 |
Exhibit 10.4 ? AMPIO PHARMACEUTICALS, INC. 2019 STOCK AND INCENTIVE PLAN ? GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Ampio Pharmaceuticals, Inc. (the ?Company?) 2019 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other key persons (including Consultants and prospective e |
|
| March 3, 2021 |
Specimen Common Stock Certificate of the Registrant. Exhibit 4.1 ? ? ? This Certifies That BY INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AUTHORIZED: 300,000,000 COMMON SHARES, $0.0001 PAR VALUE PER SHARE Fully Paid and Non-Assessable Common Stock, $0.0001 Par Value of AMPIO PHARMACEUTICALS, INC. CUSIP 03209T 10 9 SEE REVERSE FOR CERTAIN DEFINITIONS COUNTERSIGNED AND REGISTERED: EQUINITI TRUST COMPANY IN WITNESS WHEREOF, the Corporation has |
|
| March 3, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 20, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Ampio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 03209T109 (CUSIP Number) December 31, 2020** (Date of Event Which Requires Filing of This Statement) Check the appropriate box t |
|
| December 29, 2020 |
Exhibit 99.1 Ampio Receives feedback from the FDA on Ampio’s Proposed Modifications to the special protocol asssessment for Ampion treatment of severe Osteoarthritis of the knee ENGLEWOOD, Colo., December 29, 2020, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditi |
|
| December 29, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Comm |
|
| December 15, 2020 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 12, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Comm |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2020 |
Exhibit 99.1 Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results ENGLEWOOD, CO, November 5, 2020 – Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, today, at 4:30pm EST, will provide an update and overview of its clinical developm |
|
| November 3, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-351 |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 28, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizat |
|
| July 31, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35182 AMPIO |
|
| July 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizatio |
|
| July 14, 2020 |
Amendment No. 3 to Employment Agreement, dated July 13, 2020, between the Company and Daniel Stokely EX-10.1 2 tmb-20200713xex10d1.htm EX-10.1 Exhibit 10.1 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT This Amendment No. 3 to Employment Agreement (“Amendment No. 3”) is executed and entered into on July 13, 2020, (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc. (the “Company”), and Daniel Stokely (“Executive”) (collectively, the “Parties”). RECITALS WHEREAS, the Parties executed an Emplo |
|
| July 6, 2020 |
LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby constitutes and appoints each of Rebekah Cleveland, Leah Brownlee, Michael Nowak or Jackson Lieu, or either of them acting singly and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: 1. |
|
| June 19, 2020 |
Ampio to Start First Clinical Trial in COVID-19 Program Exhibit 99.1 Ampio to Start First Clinical Trial in COVID-19 Program ENGLEWOOD, Colo., June 19, 2020, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”), is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is developing therapies for patients infected with t |
|
| June 19, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizatio |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑35182 AMPIO |
|
| May 6, 2020 |
PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-237723 Up to $50,000,000 Common Stock Ampio Pharmaceuticals, Inc. We have entered into a sales agreement (the “Sales Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”) and Roth Capital Partners, LLC (“Roth,” and ThinkEquity collectively the “Sales Agents”) relating to shares of our common s |
|
| May 1, 2020 |
May 1, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 30, 2020 |
As filed with the Securities and Exchange Commission on April 30, 2020 Registration No. |
|
| April 22, 2020 |
Exhibit 10.1 LOAN AGREEMENT * * * * * * * * * * THIS LOAN AGREEMENT (“Agreement”) is made on April 16, 2020, between the Ampio Pharmaceuticals, Inc. and KEYBANK NATIONAL ASSOCIATION identified in the SBA Approval issued by the U.S. Small Business Administration (“SBA”) to Lender, dated April 10, 2020 SBA Loan Number 12795971-06 (“Approval”). SBA has authorized a guaranty of a loan from Lender to B |
|
| April 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001‑35182 26‑0179592 (State or other jurisdiction of incorporation or organizati |
|
| April 16, 2020 |
Form S-3 (Registration No. 333-237723) Table of Contents As filed with the Securities and Exchange Commission on April 16, 2020 Registration No. |
|
| April 16, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001‑35182 26‑0179592 (State or other jurisdiction of incorporation or organizati |
|
| March 24, 2020 |
Exhibit 99.1 Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19 ENGLEWOOD, Colo., March 24, 2020, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therap |
|
| March 24, 2020 |
Exhibit 99.2 Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial ENGLEWOOD, Colo., March 24, 2020, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the “Company”), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Ph |
|
| March 24, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizati |
|
| February 21, 2020 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-217094 PROSPECTUS SUPPLEMENT (to Prospectus dated April 20, 2017) Up to $50,000,000 Common Stock Ampio Pharmaceuticals, Inc. We have entered into a sales agreement (the ?Sales Agreement?) with ThinkEquity, a division of Fordham Financial Management, Inc. (?ThinkEquity?) and Roth Capital Partners, LLC (?Roth? and ThinkEquity co |
|
| February 21, 2020 |
EXHIBIT 4.5 DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value, of which no preferred shares are issued or outstanding. The following summary description of our capital stock is based on the provisions of our certificate of incorporati |
|
| February 21, 2020 |
Code of Business Conduct and Ethics. Exhibit 14.1 AMPIO PHARMACEUTICALS, INC. CODE OF BUSINESS CONDUCT AND ETHICS Adopted August 14, 2010 Updated December 13, 2019 1. Introduction This Code of Business Conduct and Ethics (the “Code”) covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide all directors, officers and employees of Ampio Pharmaceut |
|
| February 21, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001‑35182 AMPIO PHARMACEUTICALS, INC. (www.amp |
|
| February 21, 2020 |
Exhibit 10.11 AMENDMENT NO. 3 TO HUMAN SERUM ALBUMIN INGREDIENT PURCHASE AND SALE AGREEMENT This Amendment (this “Amendment”) No. 3 to the Human Serum Albumin Ingredient Purchase and Sale Agreement is made and entered into as of November 14, 2017 by and between Octapharma USA, Inc., a Virginia corporation (“Supplier”), and Ampio Pharmaceuticals, Inc., a Delaware corporation (“Customer”). Capitaliz |
|
| February 20, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2020 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organiz |
|
| February 20, 2020 |
EX-10.1 2 tm208243d3ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMPIO PHARMACEUTICALS, INC. $50,000,000 Common Stock ($0.0001 value per share) Sales Agreement February 20, 2020 ThinkEquity, a division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Ampio Pharmace |
|
| January 23, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ampio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03209T109 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 14, 2020 |
AMPE / Ampio Pharmaceuticals, Inc. 10-Q/A - Quarterly Report - 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑35182 |
|
| January 8, 2020 |
AMPE / Ampio Pharmaceuticals, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 8, 2020 Registration Nos. |
|
| January 8, 2020 |
AMPE / Ampio Pharmaceuticals, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 8, 2020 Registration Nos. |
|
| January 8, 2020 |
Ampio Pharmaceuticals, Inc. 2019 Stock and Incentive Plan Exhibit 99.1 AMPIO PHARMACEUTICALS, INC. 2019 STOCK AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Ampio Pharmaceuticals, Inc. (the “Company”) 2019 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other key persons (including Consultants and prospe |
|
| January 8, 2020 |
AMPE / Ampio Pharmaceuticals, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on January 8, 2020 Registration No. |
|
| January 8, 2020 |
Certificate of Incorporation of the Registrant, as currently in effect. Exhibit 3.1 CERTIFICATE OF INCORPORATION OF CHAY ENTERPRISES, INC. The undersigned, a natural person eighteen years of age or older, hereby establishes a corporation pursuant to the General Corporation Law of the State of Delaware and adopts the following Certificate of Incorporation which reads in its entirety as follows: ARTICLE I NAME The name of the corporation (hereinafter, the "Corporation") |
|
| January 8, 2020 |
AMPE / Ampio Pharmaceuticals, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 8, 2020 Registration Nos. |
|
| January 8, 2020 |
AMPE / Ampio Pharmaceuticals, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 8, 2020 Registration Nos. |
|
| January 7, 2020 |
AMPE / Ampio Pharmaceuticals, Inc. / Terker Bruce E - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ampio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 03209T109 (CUSIP Number) December 31, 2019** (Date of Event Which Requires Filing of This Statement) Check the appropriate box t |
|
| January 3, 2020 |
AMPE / Ampio Pharmaceuticals, Inc. CORRESP - - January 3, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 18, 2019 |
Exhibit 10.1 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 to Employment Agreement (“Amendment No. 2”) is executed on and entered into on December 14, 2019, (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc. (the “Company”), and Daniel Stokely (“Executive”) (collectively, the “Parties”). RECITALS WHEREAS, the Parties executed an Employment Agreement on July 9, 2019 set |
|
| December 18, 2019 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organ |
|
| December 18, 2019 |
Exhibit 14.1 AMPIO PHARMACEUTICALS, INC. CODE OF BUSINESS CONDUCT AND ETHICS Adopted August 14, 2010 Updated December 13, 2019 1. Introduction This Code of Business Conduct and Ethics (the “Code”) covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide all directors, officers and employees of Ampio Pharmaceut |
|
| December 18, 2019 |
EX-3.1 2 ex-3d1.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF AMPIO PHARMACEUTICALS, INC. Ampio Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Cor |
|
| December 18, 2019 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is executed on December 14, 2019 and effective as of January 10, 2020 (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and Michael Macaluso, an individual (“Executive”) (the Company and Execut |
|
| December 4, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 4, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organiza |
|
| December 4, 2019 |
Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number Exhibit 99.1 Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number ENGLEWOOD, Colo., December 4, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled “Evaluating the Efficacy and Safety of AmpionTM to treat Adult |
|
| November 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑35182 A |
|
| November 7, 2019 |
Exhibit 10.4 November 7, 2019 Dear Mr. Stokely, Reference is made to that Stock Option Cancellation and Grant Agreement for Executive, dated August 20, 2019, between Ampio Pharmaceuticals, Inc. (the “Company”) and yourself (the “Agreement”). Capitalized terms used herein and not defined shall have the meanings given them in the Agreement. Whereas, the Agreement contained an administrative error in |
|
| October 31, 2019 |
AMPE / Ampio Pharmaceuticals, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| October 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 28, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organiza |
|
| October 28, 2019 |
Form of Warrant Exercise Agreement EX-10.1 2 ex-10d1.htm EX-10.1 Exhibit 10.1 WARRANT EXERCISE AGREEMENT This Warrant Exercise Agreement (this “Agreement”), dated as of October 28, 2019, is by and between Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Holder”) of a Common Stock Purchase Warrant to purchase shares of the Company’s common stock, par value $0.0001 per share (the “ |
|
| October 16, 2019 |
AMPE / Ampio Pharmaceuticals, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| October 10, 2019 |
Exhibit 99.1 Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility ENGLEWOOD, Colo., October 10, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled “Evaluating the Efficacy and Safety of AmpionTM to trea |
|
| October 10, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organiza |
|
| September 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organi |
|
| September 20, 2019 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is executed on and entered into as of September 16, 2019, (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and Holli Cherevka, an individual (“Executive”) (the Company and Executive each a “Pa |
|
| September 20, 2019 |
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial EX-99.2 4 ex-99d2.htm EX-99.2 Exhibit 99.2 Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial ENGLEWOOD, Colo., September 17, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced the progress to date in the Company’s special protocol assessment (SPA) phase three clinical trial titled, “A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy |
|
| September 20, 2019 |
Ampio Retains Legal Counsel for Transaction Advisory Committee Exhibit 99.1 Ampio Retains Legal Counsel for Transaction Advisory Committee ENGLEWOOD, Colo., September 18, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled “Evaluating the Efficacy and Safety of Ampion to treat Adults with Pain Due to Severe Osteoart |
|
| August 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001‑35182 26‑0179592 (State or other jurisdiction of incorporation or organizat |
|
| August 23, 2019 |
EX-10.2 3 ex-10d2.htm EX-10.2 Exhibit 10.2 AMPIO PHARMACEUTICALS, INC. 2010 STOCK OPTION AND INCENTIVE PLAN STOCK OPTION CANCELLATION AND GRANT AGREEMENT FOR EXECUTIVE THIS STOCK OPTION CANCELLATION AND GRANT AGREEMENT FOR EXECUTIVE (“Agreement”) is made and entered into as of the 20th day of August, 2019 (“Grant Date”) by and between Ampio Pharmaceuticals, Inc. (the “Company” or “we”) and Daniel |
|
| August 23, 2019 |
Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (“Amendment”) is executed on and entered into on August 20, 2019, (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc. (the “Company”), and Daniel Stokely (“Executive”) (collectively, the “Parties”). RECITALS WHEREAS, the Parties executed an Employment Agreement on July 9, 2019 setting forth certain t |
|
| August 9, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑35182 AMPIO |
|
| July 11, 2019 |
Ampio Appoints Moss Adams LLP as the Company’s new Independent Auditor EX-99.2 3 ex-99d2.htm EX-99.2 Exhibit 99.2 Ampio Appoints Moss Adams LLP as the Company’s new Independent Auditor ENGLEWOOD, Colo., July 11, 2019, /PRNewswire/ - Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited trea |
|
| July 11, 2019 |
Exhibit 16.1 July 11, 2019 Richard Giles Audit Committee Chair Ampio Pharmaceuticals, Inc. 373 Inverness Parkway, Suite 200 Englewood, Colorado 80112 Dear Mr. Giles: We have read item 4.01 to be included in the Form 8-K of Ampio Pharmaceuticals, Inc. to be filed with the Securities and Exchange Commission regarding its change in auditors. We are in agreement with the statements made regarding our |
|
| July 11, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizatio |
|
| July 10, 2019 |
Ampio Appoints Dan Stokely as the Company’s new Chief Financial Officer EX-99.1 3 ex-99d1.htm EX-99.1 Exhibit 99.1 Ampio Appoints Dan Stokely as the Company’s new Chief Financial Officer ENGLEWOOD, Colo., July 10, 2019, /PRNewswire/ - Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited tre |
|
| July 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001‑35182 26‑0179592 (State or other jurisdiction of incorporation or organization |
|
| July 10, 2019 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is executed on and entered into as of July 9, 2019, (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and Daniel Stokely, an individual (“Executive”) (the Company and Executive each a “Party” a |
|
| June 20, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ampio Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03209T109 (CUSIP Number) June 17, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 19, 2019 |
Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering ENGLEWOOD, Colo. |
|
| June 19, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizatio |
|
| June 17, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizatio |
|
| June 17, 2019 |
Exhibit 10.3 Form of Lock-Up Agreement [•], 2019 ThinkEquity A Division of Fordham Financial Management, Inc. 17 State Street, 22nd Fl New York, NY 10004 Ladies and Gentlemen: The undersigned understands that ThinkEquity, a division of Fordham Financial Management, Inc., (the “Placement Agent”) proposes to enter into an Placement Agency Agreement (the “Placement Agency Agreement”) with Ampio Pharm |
|
| June 17, 2019 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT June 17, 2019 ThinkEquity, a division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 Ladies and Gentlemen: Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engage |
|
| June 17, 2019 |
Form of Securities Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 17, 2019, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” a |
|
| June 17, 2019 |
Ampio Pharmaceuticals Announces Pricing of Public Offering Exhibit 99.1 Ampio Pharmaceuticals Announces Pricing of Public Offering ENGLEWOOD, Colo., June 17, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced today that it will offer up to $12 Million of its common stock in public offering. Ampio has entered into purchase agreements for the purchase of an aggregate 25,320,000 common shares of the Company at an offering |
|
| June 17, 2019 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-217094 PROSPECTUS SUPPLEMENT (to Prospectus dated April 20, 2017) 30,000,000 Shares Common Stock Ampio Pharmaceuticals, Inc. We are offering 30,000,000 shares of our common stock, par value $0.0001 per share, in this offering at a negotiated price of $0.40 per share to certain investors that are not affiliated with us pursuant to this prospectu |
|
| June 17, 2019 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-217094 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and |
|
| June 14, 2019 |
Prospectus Supplement dated June 14, 2019 EXPLANATORY NOTE Filed Pursuant to Rule 424(b)(5) Registration No. 333-217094 PROSPECTUS SUPPLEMENT (to Prospectus dated April 20, 2017) This prospectus supplement supplements our prospectus supplement dated April 15, 2019 relating to our Equity Distribution Agreement with Canaccord Genuity LLC. Please see the “Explanatory Note” contained herein. Investing in our common stock involves a high degree of risk. See “R |
|
| June 14, 2019 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizatio |
|
| June 14, 2019 |
Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock ENGLEWOOD, Colo., June 14, 2019 /PRNewswire/ - Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (“Ampio”), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Ampio expects to grant the underwriters a 45-day option to purchase additional shares o |
|
| June 14, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizatio |
|
| June 14, 2019 |
Ampio Regulatory and Clinical Update Exhibit 99.1 Ampio Regulatory and Clinical Update ENGLEWOOD, Colo., June 14, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that it received FDA approval of the Company’s special protocol assessment (SPA) of a clinical protocol titled “A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adu |
|
| June 13, 2019 |
Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (“Agreement”) is made by and between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 (“Ampio” or “Company”), together with its affiliates, shareholders, directors, officers, employees, representatives, attorneys, predecessors, successors, and assigns (collectively |
|
| June 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizatio |
|
| May 22, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organization |
|
| May 22, 2019 |
Ampio Clinical, Regulatory and Corporate Update Exhibit 99.1 Ampio Clinical, Regulatory and Corporate Update ENGLEWOOD, Colo., May 22, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates on subjects of interest to shareholders. Clinical: The results of the AP-003-C open label extension study outlining the safety and efficacy of repeat injections of AmpionTM in patients with severe osteoarthritis-of-the-knee |
|
| May 10, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑35182 AMPIO |
|
| April 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2019 AMPIO PHARMACEUTICALS, INC. (Exact name of registrant as specified in Charter) Delaware 001-35182 26-0179592 (State or other jurisdiction of incorporation or organizati |
|
| April 30, 2019 |
Ampio Pharmaceuticals Provides Regulatory Update Exhibit 99.1 Ampio Pharmaceuticals Provides Regulatory Update ENGLEWOOD, Colo., April 29, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has received comments from the U.S. Food and Drug Administration (FDA) regarding their Special Protocol Assessment (SPA). The FDA recommended the Company not start their confirmatory trial without obtaining FDA concurren |
